Form 4: Allovir Director David Hallal Receives 35,000 Restricted Stock Units

David Hallal, a director of Allovir, Inc., acquired 35,000 restricted stock units on June 6, 2024, according to a recent SEC filing.

Summary

• On June 6, 2024, David Hallal, a director of Allovir, Inc., was granted 35,000 Restricted Stock Units (RSUs) under the company's 2020 Stock Option and Grant Plan.
• These RSUs will vest on the earlier of June 6, 2025, or the date of the next annual meeting of Allovir's stockholders, contingent upon Hallal's continued service on the Board of Directors.
• Following this transaction, Hallal directly owns 2,143,662 shares of Allovir common stock.
• Hallal also has indirect ownership through The Hallal Family Irrevocable Trust 2012 (720,965 shares), the Terrie A. Hallal Family Irrevocable Trust 2012 (138,153 shares), and ElevateBio LLC (16,674,766 shares).

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock units granted to a director. It doesn't inherently indicate positive or negative performance, but rather a routine compensation practice.

Positives

• The grant of RSUs to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Future Outlook

The vesting of the RSUs is contingent upon continued service on the Board of Directors, suggesting an expectation of Hallal's continued involvement with Allovir.

Industry Context

Stock grants and RSU awards are common forms of compensation for directors and executives in publicly traded companies, particularly in the biotechnology industry, to align their interests with those of shareholders and incentivize long-term value creation.

Stakeholder Impact

• The RSU grant could have a slightly positive impact on shareholder sentiment as it aligns the director's interests with those of the shareholders.

Key Dates